Chimeric Therapeutics Ltd
ASX:CHM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chimeric Therapeutics Ltd
Cash from Operating Activities
Chimeric Therapeutics Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-192%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash from Operating Activities
-AU$7.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
-AU$17.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$65.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-58%
|
|
Chimeric Therapeutics Ltd
Glance View
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.
See Also
What is Chimeric Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-7.3m
AUD
Based on the financial report for Jun 30, 2025, Chimeric Therapeutics Ltd's Cash from Operating Activities amounts to -7.3m AUD.
What is Chimeric Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-192%
Over the last year, the Cash from Operating Activities growth was 3%. The average annual Cash from Operating Activities growth rates for Chimeric Therapeutics Ltd have been 18% over the past three years , -192% over the past five years .
